Table 2 Correlation between CLDN7 and clinicopathological features in clinically confirmed BC samples [n (%)]
From: Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer
Clinicopathological features | Total | CLDN7 high expression | CLDN7 low expression | χ2 | P |
|---|---|---|---|---|---|
|  | (N = 92) | (N = 52) | (N = 40) |  |  |
Age/year | Â | Â | Â | 0.031 | 0.859 |
<60 | 63(68.48) | 36(69.23) | 27(67.50) | Â | Â |
≥ 60 | 29(31.52) | 16(30.77) | 13(32.50) |  |  |
Histological grade | Â | Â | Â | 0.117 | 0.943 |
I | 29(31.52) | 16(30.77) | 13(32.50) | Â | Â |
II | 36(39.13) | 20(38.46) | 16(40.00) | Â | Â |
III | 27(29.35) | 16(30.77) | 11(27.50) | Â | Â |
Clinical stage | Â | Â | Â | 0.449 | 0.799 |
I | 26(28.26) | 14(26.92) | 12(30.00) | Â | Â |
II | 40(43.48) | 22(42.31) | 18(45.00) | Â | Â |
III | 26(28.26) | 16(30.77) | 10(25.00) | Â | Â |
Tumor size(cm) | Â | Â | Â | 0.054 | 0.816 |
<2 | 61(66.30) | 35(67.31) | 26(65.00) | Â | Â |
≥ 2 | 31(33.70) | 17(32.69) | 14(35.00) |  |  |
Lymph node metastasis | Â | Â | Â | 6.988 | 0.008 |
N0 | 50(54.35) | 22(42.31) | 28(70.00) | Â | Â |
N1 + N2 + N3 | 42(45.65) | 30(57.69) | 12(30.00) |  |  |
Distant metastasis | Â | Â | Â | 6.776 | 0.009 |
M0 | 68(73.91) | 33(63.46) | 35(87.50) | Â | Â |
M1 | 24(26.09) | 19(36.54) | 5(12.50) | Â | Â |
ER | Â | Â | Â | 0.033 | 0.855 |
- | 47(51.09) | 27(51.92) | 20(50.00) | Â | Â |
+ | 45(48.91) | 25(48.08) | 20(50.00) | Â | Â |
HER-2 | Â | Â | Â | 5.12 | 0.024 |
- | 62(67.39) | 30(57.69) | 32(80.00) | Â | Â |
+ | 30(32.61) | 22(42.31) | 8(20.00) | Â | Â |
PR | Â | Â | Â | 0.097 | 0.755 |
- | 50(54.35) | 29(55.77) | 21(52.50) | Â | Â |
+ | 42(45.65) | 23(44.23) | 19(47.50) | Â | Â |
Type of molecule | Â | Â | Â | 5.68 | 0.128 |
Luminal A | 16(17.39) | 7(13.46) | 9(22.50) | Â | Â |
Luminal B | 25(27.17) | 11(21.15) | 14(35.00) | Â | Â |
HER2 enriched | 26(28.26) | 19(36.54) | 7(17.50) | Â | Â |
TNBC | 25(27.17) | 15(28.85) | 10(25.00) | Â | Â |